How were GSK’s historical Lamictal (lamotrigine) sales trending?
GSK’s Lamictal brand (lamotrigine) has historically been a major contributor to its neurology portfolio, especially in epilepsy. Demand rose as the brand expanded internationally and as clinical use broadened across seizure types and patient subgroups. Over time, growth slowed in mature markets as competition increased and prescribing patterns shifted.
What products or indications drove most of Lamictal revenue for GSK?
Lamictal revenue has mainly been driven by epilepsy use (including maintenance and broader seizure management in many markets). In some geographies and periods, demand also benefited from broader neurologic adoption and prescriber comfort with long-term lamotrigine therapy.
When did Lamictal sales start to decline (and why)?
A common pattern for major branded anti-epileptics is that sales slow once:
- Generic versions enter key markets, reducing brand price realization.
- Competitors gain share through similar dosing options, formulations, or local payer preferences.
- Patent or exclusivity protection ends, tightening pricing and margins.
Because the specific timing depends on country-by-country patent and generic entry dates, the exact start of decline varies by market.
How did the generic launch affect GSK’s Lamictal numbers?
Once generics launch, brand sales typically fall sharply due to lower-cost alternatives. Even if some patients remain on the originator brand, overall market penetration shifts toward generics, and remaining branded volume becomes harder to sustain.
Where did Lamictal matter most for GSK historically—US, Europe, or elsewhere?
Lamictal was a significant brand across multiple large epilepsy markets, with the biggest revenue impact coming from geographies where lamotrigine prescribing is high and where exclusivity lasted longest before generic competition. After generic entry, the relative contribution of those markets to GSK’s branded revenue generally dropped.
What counts as “Lamictal sales” in older company reporting?
Historical “sales” can be reported differently depending on the document:
- Total product sales vs. net sales (after rebates/discounts)
- Specific geography totals (US/EU/rest-of-world)
- Brand vs. broader neurology segment performance
- Fiscal-year vs. quarterly reporting
Those definitions can change what you see in the numbers.
If you’re looking for numbers: what do you need to pinpoint the right dataset?
To provide accurate historical sales figures, you need at least one of the following:
- Year range (e.g., 2005–2010 vs. 2015–2019)
- Geography (global, US, Europe, or a specific country)
- Whether you want reported “sales” or “net sales”
- Whether you want GSK brand-level sales or segment-level context
Reply with the years and region you mean by “historic,” and I can map the requested period to the relevant reporting format you’re looking for.